U. A. Yelemanov

Study of the pharmacokinetics of non-immunogenic staphylokinase in patients with acute myocardial infarction and acute ischemic stroke

Сергей Витальевич Иванов, Igor P. Beletsky, Marina V. Zakharova, Э. А. Пономарев et autres

The aim. To investigate the pharmacokinetic parameters of non-immunogenic staphylokinase (Fortelyzin®, SuperGene LLC, Russia) in patients with acute myocardial infarction with ST-segment elevation (STEMI) on the electrocardiogram and in patients with ischemic stroke. Materials and methods. The clinical study was conducted in …

ru (code pays fourni par la source)

Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study

Nikolay A Shamalov, Dina Rustemovna Khasanova, Sergey Marchenko, М. А. Солдатов et autres

Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment. Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS …

ru, by (code pays fourni par la source)

Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)

Evgeny I. Gusev, M. Yu. Martynov, Nikolay A Shamalov, Elena Borisovna Yarovaya et autres

ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение эффективности и безопасности неиммуногенной стафилокиназы (НС) в сравнении с алтеплазой (А) у пациентов с ишемическим инсультом (ИИ) в первые 4,5 ч от развития симптомов. МАТЕРИАЛ И МЕТОДЫ В открытом рандомизированном сравнительном исследовании «не меньшей эффективности» в параллельных группах НС …

ru, us (code pays fourni par la source)

Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial

Eugene I. Gusev, M. Yu. Martynov, Alexey A Nikonov, Nikolay A Shamalov et autres

ru (code pays fourni par la source)